The FDA’s Pharmacy Compounding Advisory Committee will convene this summer to discuss seven peptides that are currently restricted from use in compounded medications. More: FDA advisory committee set to weigh taking action on certain unapproved peptides Source: fierce
read moreWith Daiichi Sankyo’s priorities increasingly tied to its innovative medicines—and its oncology portfolio in particular—the Tokyo-based drugmaker is following in the footsteps of several of its peers with a deal to split from its consumer health business. More: In industry's
read moreThe company and its global distrubution partner the Global Fund expanded its commitment to bring Yeztugo to 3 million people worldwide by 2028, but Doctors Without Borders (MSF) says supply is still “not nearly enough.” More: Gilead widens global Yeztugo
read moreAI heavyweight Anthropic has appointed Novartis CEO Vas Narasimhan to its board of directors as the link between the pharmaceutical industry and Silicon Valley deepens. More: Novartis CEO Vas Narasimhan joins Anthropic’s board as biopharma’s ties to AI deepen Source:
read moreFor Astellas’ chief manufacturing officer, Rao Mantri, Ph.D., production is not just about a reliable supply of a pharmaceutical product. Manufacturing serves as a crucial bridge that helps link promising research to patients in the real world, too. More: Astellas
read more© 1994 - 2026 B.M. Pharmaceuticals